home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2889.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
3KB
|
45 lines
Document 2889
DOCN M94A2889
TI Pilot study of zidovudine (AZT) and zalcitabine (ddC) combination in
HIV-associated dementia.
DT 9412
AU McIntyre K; Torres R; Luck D; Tavalouras G; St. Vincent's Hospital and
Medical Center of New York, N.Y.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):201 (abstract no. PB0233). Unique
Identifier : AIDSLINE ICA10/94369686
AB OBJECTIVE: To evaluate the safety and efficacy of zidovudine (AZT) and
zalcitabine (ddC) combination therapy in patients with HIV-associated
dementia, who have been previously treated with zidovudine. METHODS:
HIV-infected patients were eligible for the study if they had received
zidovudine for a minimum of 4 weeks and had obtained abnormal scores on
at least two of six neuropsychological tests and had no other organic or
psychological cause of dementia. All patients had baseline and
neuropsychological testing, neurological examinations, lumbar punctures,
CT or MRI scans and SPECT scans before starting therapy with zidovudine
600 mg/day and zalcitabine 2.25 mg/day. After 8 weeks of therapy,
neuropsychological tests, neurological exams and lumbar punctures were
repeated. CSF and serum HIV-RNA titers at baseline and at 8 weeks were
determined with quantitative PCR and concentrations of both nucleosides
were determined in plasma and CSF samples at 8 weeks. RESULTS: Four
patients with mild-to-moderate HIV-associated dementia who met
eligibility criteria were treated with the combination of nucleosides
for 8 weeks. Three patients who completed the 8 weeks of treatment were
evaluable. The mean serum and CSF HIV-RNA titers of 2 patients decreased
from 26,685 and 786 to 16,742 and 66, respectively. Neuropsychological
scores improved in all three patients after 8 weeks of therapy, and a
53% improvement from baseline was observed in macro-neurological
function. No adverse experiences were noted. CONCLUSION: Combination
therapy with zidovudine and zalcitabine is effective in reversing
neurocognitive dysfunction and serum and CSF HIV-RNA titers in patients
with HIV-associated dementia.
DE AIDS Dementia Complex/*DRUG THERAPY/MICROBIOLOGY/PSYCHOLOGY Drug
Therapy, Combination Human HIV/ISOLATION & PURIF Neuropsychological
Tests Pilot Projects RNA, Viral/BLOOD/CEREBROSPINAL FLUID Treatment
Outcome Viremia/DRUG THERAPY Zalcitabine/ADMINISTRATION &
DOSAGE/*THERAPEUTIC USE Zidovudine/ADMINISTRATION & DOSAGE/*THERAPEUTIC
USE CLINICAL TRIAL MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).